AnaptysBio Secures $40 Million Series D Financing
Enables Advancement of First-In-Class Anti-Inflammatory Antibody Programs Through Key Clinical Studies
SAN DIEGO, July 15, 2015 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology, today announced the completion of an oversubscribed $40MM Series D financing round. Participants in this financing round include BVF Partners L.P. and its affiliates, BioMed Ventures, Cormorant Asset Management, Frazier Healthcare, HBM Healthcare Investments, Longwood Capital Partners, Novo A/S and additional undisclosed investors.
Proceeds from the financing are intended to advance AnaptysBio's first-in-class anti-IL-33 and anti-IL-36 receptor antibody programs through key Phase II studies. The financing will also support the continued discovery of novel therapeutic antibodies against emerging target biology in inflammation and immuno-oncology using AnaptysBio's proprietary somatic hypermutation-based antibody discovery platform.
"The proceeds of this financing provide AnaptysBio with the financial strength to potentially demonstrate efficacy of our anti-IL-33 program in severe adult asthma and peanut allergy patients, while also advancing our anti-IL-36 receptor program to proof-of-concept in generalized pustular psoriasis," said Hamza Suria, President & CEO of AnaptysBio. "We are pleased to welcome such highly respected investors to our shareholder base. Their investment provides strong endorsement of the quality of our pipeline, platform and the team we have built at AnaptysBio."
About AnaptysBio
AnaptysBio is a privately-held antibody development company focused on novel programs in immuno-oncology and inflammation. The Company's first-in-class proprietary pipeline includes ANB020, an anti-IL-33 antibody for the treatment of severe adult asthma and peanut allergy, and ANB019, an anti-IL-36 receptor antibody for the treatment of generalized pustular psoriasis. AnaptysBio's SHM-XEL platform has pioneered the use of in vitro somatic hypermutation for antibody discovery and optimization, which replicates key features of the human immune system and overcomes limitations of prior antibody technologies. AnaptysBio has previously announced partnerships with several biopharmaceutical companies, including Novartis, Gilead, Celgene, Momenta and TESARO. For more information, visit www.anaptysbio.com.
Logo - http://photos.prnewswire.com/prnh/20111205/SF16052LOGO
SOURCE AnaptysBio
Share this article